CLV IntelligenceReimbursement Policy Monitoring

Alert detail

FDA Approval: RINVOQ (UPADACITINIB) — Type 3 - New Dosage Form

Policy ID: FDA-NDA218347Specialty: RheumatologyAdded: 7/8/2026Effective: April 26, 2024federal register
Low

What changed

New FDA drug approval. Coverage and billing pathway depend on the FDA label and applicable Medicare LCDs/NCDs — for very recent approvals the label may not be posted yet. Verify against the FDA label and current coverage policy before billing.

Who’s affected: Rheumatology billing teams · Effective: April 26, 2024

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

View subscription plansCreate a free account

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Rheumatology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Rheumatology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Rheumatology— the week’s changes and deadlines, delivered to your inbox. No account required.